According to the WHO 2021 classification of central nervous system tumors, isocitrate dehydrogenase (IDH) status is considered as a critical biomarker for the diagnosis and treatment of glioma and plays a vital role in prognosis and treatment strategies (3, 4). This evidence concerns the gene IDH2 and glioma.